Literature DB >> 31582562

The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity.

Tuong-Vi Nguyen1, Shihua Yao1, Yahong Wang2, Alan Rolfe1, Anand Selvaraj1, Rachel Darman1, Jiyuan Ke1, Markus Warmuth1, Peter G Smith1, Nicholas A Larsen1, Lihua Yu1, Ping Zhu1, Peter Fekkes1, Frédéric H Vaillancourt1, David M Bolduc3.   

Abstract

DNMT3A (DNA methyltransferase 3A) is a de novo DNA methyltransferase responsible for establishing CpG methylation patterns within the genome. DNMT3A activity is essential for normal development, and its dysfunction has been linked to developmental disorders and cancer. DNMT3A is frequently mutated in myeloid malignancies with the majority of mutations occurring at Arg-882, where R882H mutations are most frequent. The R882H mutation causes a reduction in DNA methyltransferase activity and hypomethylation at differentially-methylated regions within the genome, ultimately preventing hematopoietic stem cell differentiation and leading to leukemogenesis. Although the means by which the R882H DNMT3A mutation reduces enzymatic activity has been the subject of several studies, the precise mechanism by which this occurs has been elusive. Herein, we demonstrate that in the context of the full-length DNMT3A protein, the R882H mutation stabilizes the formation of large oligomeric DNMT3A species to reduce the overall DNA methyltransferase activity of the mutant protein as well as the WT-R882H complex in a dominant-negative manner. This shift in the DNMT3A oligomeric equilibrium and the resulting reduced enzymatic activity can be partially rescued in the presence of oligomer-disrupting DNMT3L, as well as DNMT3A point mutations along the oligomer-forming interface of the catalytic domain. In addition to modulating the oligomeric state of DNMT3A, the R882H mutation also leads to a DNA-binding defect, which may further reduce enzymatic activity. These findings provide a mechanistic explanation for the observed loss of DNMT3A activity associated with the R882H hot spot mutation in cancer.
© 2019 Nguyen et al.

Entities:  

Keywords:  DNA methylation; DNA methyltransferase; DNMT3A; R882H; cancer; cancer biology; epigenetics; oligomer; oligomerization

Mesh:

Substances:

Year:  2019        PMID: 31582562      PMCID: PMC6851320          DOI: 10.1074/jbc.RA119.010126

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.

Authors:  David A Russler-Germain; David H Spencer; Margaret A Young; Tamara L Lamprecht; Christopher A Miller; Robert Fulton; Matthew R Meyer; Petra Erdmann-Gilmore; R Reid Townsend; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

2.  Histone tails regulate DNA methylation by allosterically activating de novo methyltransferase.

Authors:  Bin-Zhong Li; Zheng Huang; Qing-Yan Cui; Xue-Hui Song; Lin Du; Albert Jeltsch; Ping Chen; Guohong Li; En Li; Guo-Liang Xu
Journal:  Cell Res       Date:  2011-05-24       Impact factor: 25.617

3.  Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family.

Authors:  Zhao-Xia Chen; Jeffrey R Mann; Chih-Lin Hsieh; Arthur D Riggs; Frédéric Chédin
Journal:  J Cell Biochem       Date:  2005-08-01       Impact factor: 4.429

4.  Dnmt3a is essential for hematopoietic stem cell differentiation.

Authors:  Grant A Challen; Deqiang Sun; Mira Jeong; Min Luo; Jaroslav Jelinek; Jonathan S Berg; Christoph Bock; Aparna Vasanthakumar; Hongcang Gu; Yuanxin Xi; Shoudan Liang; Yue Lu; Gretchen J Darlington; Alexander Meissner; Jean-Pierre J Issa; Lucy A Godley; Wei Li; Margaret A Goodell
Journal:  Nat Genet       Date:  2011-12-04       Impact factor: 38.330

5.  Array-based genomic resequencing of human leukemia.

Authors:  Y Yamashita; J Yuan; I Suetake; H Suzuki; Y Ishikawa; Y L Choi; T Ueno; M Soda; T Hamada; H Haruta; S Takada; Y Miyazaki; H Kiyoi; E Ito; T Naoe; M Tomonaga; M Toyota; S Tajima; A Iwama; H Mano
Journal:  Oncogene       Date:  2010-04-19       Impact factor: 9.867

6.  Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.

Authors:  Rui Lu; Ping Wang; Trevor Parton; Yang Zhou; Kaliopi Chrysovergis; Shira Rockowitz; Wei-Yi Chen; Omar Abdel-Wahab; Paul A Wade; Deyou Zheng; Gang Greg Wang
Journal:  Cancer Cell       Date:  2016-06-23       Impact factor: 31.743

7.  DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells.

Authors:  Jie Xu; Yue-Ying Wang; Yu-Jun Dai; Wu Zhang; Wei-Na Zhang; Shu-Min Xiong; Zhao-Hui Gu; Kan-Kan Wang; Rong Zeng; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-04       Impact factor: 11.205

8.  A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells.

Authors:  Soo Jin Kim; Hongbo Zhao; Swanand Hardikar; Anup Kumar Singh; Margaret A Goodell; Taiping Chen
Journal:  Blood       Date:  2013-10-28       Impact factor: 22.113

9.  A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3AR882) Demonstrates a Causal Relationship between Its Dominant-Negative Effect and Leukemogenesis.

Authors:  Rui Lu; Jun Wang; Zhihong Ren; Jiekai Yin; Yinsheng Wang; Ling Cai; Gang Greg Wang
Journal:  Cancer Res       Date:  2019-06-04       Impact factor: 13.312

10.  DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.

Authors:  L Scourzic; L Couronné; M T Pedersen; V Della Valle; M Diop; E Mylonas; J Calvo; E Mouly; C K Lopez; N Martin; M Fontenay; A Bender; S Guibert; P Dubreuil; P Dessen; N Droin; F Pflumio; M Weber; P Gaulard; K Helin; T Mercher; O A Bernard
Journal:  Leukemia       Date:  2016-02-15       Impact factor: 11.528

View more
  6 in total

1.  Base editor scanning charts the DNMT3A activity landscape.

Authors:  Nicholas Z Lue; Emma M Garcia; Kevin C Ngan; Ceejay Lee; John G Doench; Brian B Liau
Journal:  Nat Chem Biol       Date:  2022-10-20       Impact factor: 16.174

2.  DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.

Authors:  Majd Jawad; Michelle Afkhami; Yi Ding; Xiaohui Zhang; Peng Li; Kim Young; Mina Luqing Xu; Wei Cui; Yiqing Zhao; Stephanie Halene; Aref Al-Kali; David Viswanatha; Dong Chen; Rong He; Gang Zheng
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

3.  Methylation of recombinant mononucleosomes by DNMT3A demonstrates efficient linker DNA methylation and a role of H3K36me3.

Authors:  Alexander Bröhm; Tabea Schoch; Michael Dukatz; Nora Graf; Franziska Dorscht; Evelin Mantai; Sabrina Adam; Pavel Bashtrykov; Albert Jeltsch
Journal:  Commun Biol       Date:  2022-03-02

4.  Chinese Medicine Regulates DNA Methylation to Treat Haematological Malignancies: A New Paradigm of "State-Target Medicine".

Authors:  Feng-Lin Shen; Yan-Na Zhao; Xiao-Ling Yu; Bo-Lin Wang; Xiao-Long Wu; Gao-Chen Lan; Rui-Lan Gao
Journal:  Chin J Integr Med       Date:  2021-07-09       Impact factor: 1.978

Review 5.  Alterations to DNMT3A in Hematologic Malignancies.

Authors:  Kartika Venugopal; Yang Feng; Daniil Shabashvili; Olga A Guryanova
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 13.312

6.  Tau Oligomers and Fibrils Exhibit Differential Patterns of Seeding and Association With RNA Binding Proteins.

Authors:  Lulu Jiang; Jian Zhao; Ji-Xin Cheng; Benjamin Wolozin
Journal:  Front Neurol       Date:  2020-09-30       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.